I agree, Trudy. Personally, I have kind of a love/hate relationship with diagnoses, both in principle and in fact. The main reason for a DX--any DX--is to justify a certain therapeutic course of action. Bully for Big Pharma (and for research based on pharmaceutical treatment protocols), but less meaningful, in many ways, to the actual sufferers. Yes, I know that patients like a diagnosis as a kind of "closure", and it is true that doctors would be irresponsible to begin harsh treatments without a clear path to some sort of remediation. Yet the bottom line is that, when you hurt, you hurt. The rest is, as they say, commentary.
I think that it is a good start that the present nomenclature does allow for many variations along several continua: Vasculitic vs. granulomatous characterization; ANCA positive vs. ANCA negative presentation; C-ANCA/P-ANCA/Atypical ANCA in any combination; and so on. There are a few normal (but not definitive) correlations, which is why certain names have a ring (but no guarantee) of certainty: Upper airway involvement is less usual for P-ANCA than for C-ANCA (as I have always had P-ANCA, this describes me); Granulomas are more associated with C-ANCA (my biopsies have suggested "vague garnulomatous formations", but nothing obvious); P-ANCA correlates more highly with kidney involvement (both correlate highly with lung involvement, though there there are fewer P-ANCA patients without lung involvement than C-ANCA patients); some sort of ANCA correlation is present in about 90 percent of those with any of the known vasculidities that we think of as "WG". Nevertheless, I am not a big fan of thinking of names as having magical powers. They are, to me, a feature of conversation. That is all.
Al
Bookmarks